Vertex Pharmaceuticals | VRTX

Stock Price
523.93
Daily Change
-11.24 -2.10%
Monthly
0.30%
Yearly
24.33%
Q4 Forecast
512.82

EPS Reference Time Actual Consensus Previous
2026-11-02 FY2026Q3 PM 4.88 4.80
2026-08-03 FY2026Q2 PM 4.73 4.72 4.52
2026-05-04 FY2026Q1 PM 4.47 4.43 4.06
2026-02-12 FY2025Q4 PM 5.03 5.12 3.98
2025-11-03 FY2025Q3 PM 4.80 4.62 4.38



Peers Price Chg Day Year Date
AbbVie 285.64 0.45 0.16% 25.29% Oct/23
Acadia Pharmaceuticals 19.73 -0.58 -2.86% -10.40% Oct/23
Agios Pharmaceuticals 37.00 -0.19 -0.51% -14.61% Oct/23
Alnylam Pharmaceuticals 224.03 -3.25 -1.43% -51.66% Oct/23
Amgen 439.40 -7.88 -1.76% 50.60% Oct/23
Arrowhead Research 58.02 -0.34 -0.58% 52.68% Oct/23
Biogen 250.69 -3.15 -1.24% 67.25% Oct/23
BioMarin Pharmaceutical 55.95 -0.68 -1.20% 2.70% Oct/23
Bristol-Myers Squibb 61.48 -1.52 -2.41% 40.27% Oct/23
Gilead Sciences 156.04 -1.15 -0.73% 29.02% Oct/23

Indexes Price Day Year Date
US Index 500 7624 -39.75 -0.52% 12.25% Oct/23
USND 25955 -53.52 -0.21% 11.85% Oct/23
US Index 400 3617 -20.35 -0.56% 9.64% Oct/23
US Index 100 28958 -1.16 -0.004% 14.19% Oct/23

Vertex Pharmaceuticals traded at $523.93 this Friday October 23rd, decreasing $11.24 or 2.10 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals lost 0.30 percent. Over the last 12 months, its price rose by 24.33 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 512.82 by the end of this quarter and at 480.89 in one year, according to Trading Economics global macro models projections and analysts expectations.

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.



News Stream
Vertex Pharmaceuticals Shares Hit 8-week Low
Vertex Pharmaceuticals shares decreased to 500.75 USD, the lowest since August 2026. Over the past 4 weeks, Vertex Pharmaceuticals lost 9.77%, and in the last 12 months, it increased 22.87%.
2026-10-02
Vertex Pharmaceuticals Stock Price Hits 4-week Low
Vertex Pharmaceuticals shares decreased to 511.15 USD, the lowest since August 2026. Over the past 4 weeks, Vertex Pharmaceuticals lost 0.64%, and in the last 12 months, it increased 30.27%.
2026-09-15
Vertex Pharmaceuticals Stock Price Hits All-time High
Vertex Pharmaceuticals shares increased to an all-time high of 555.98 USD. Over the past 4 weeks, Vertex Pharmaceuticals gained 17.8%, and in the last 12 months, it increased 38.28%.
2026-09-02